Nature-inspired Nanoparticle Adiposomes Enable Targeted Delivery of Hydrophobic Drug for Anti-Cancer Treatment

The predominance of lipophilic molecules in drug pipelines poses a fundamental delivery challenge in the aqueous physiological environment. Inspired by the endogenous lipid-transport machinery of lipid droplets and lipoproteins, adiposome was developed as a biocompatible platform for hydrophobic drug delivery. Here, docetaxel (DTX) was selected as a model hydrophobic chemotherapeutic agent to evaluate the therapeutic versatility of adiposome. Non-targeted DTX-loaded adiposomes (DTX-Ad) reduced systemic toxicity by avoiding the allergenic excipients Tween 80 and ethanol used in commercial DTX formulations. The cytotoxic mechanism and intracellular responses of DTX-Ad were comprehensively characterized. To boost antitumor efficacy, three tumor-targeting DTX-Ad formulations were subsequently engineered. Lung-targeting DTX-adiposomes (Lung@DTX-Ad), mediated by AAM-B1-28-CRGDK fusion peptide/NRP1 axis, enhanced antitumor efficacy in a lung metastasis model. BCMA-targeting DTX-adiposomes (BCMA@DTX-Ad), conferred by biotin-avidin-mediated antibody conjugation, achieved sustained suppression in a multiple myeloma model. Liver-targeting DTX-adiposomes (Liver@DTX-Ad), enabled by the ApoE/LDLR axis, outperformed both commercial DTX injection and sorafenib in hepatocellular carcinoma models. Taken together, these results demonstrate adiposome as a promising and broadly applicable drug delivery platform, with considerable potential for clinical translation across diverse malignancies.